跳至主要内容
临床试验/NCT03107078
NCT03107078Unknown4 期

Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial

Jie Shen1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2016年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
200
试验地点
1
主要终点
Number of patients defined as Unchange for the Glucocorticoids Treatment based on the 7 parameters of eye assessment

研究概览

简要总结

For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is not satisfied. Investigators established a novel classification of TAO for the first time to assess more precisely for better personal treatment.

详细描述

TAO is one of most common extra thyroid manifestation of dysfunctional thyroid disease. Since the morbidity of TAO has been increasing rapidly, Investigators' team is intended to verify the feasibility of the new type of classification system established by the related parameters of orbital MRI scan. Based on classification, investigators compare the efficacy of two GCs therapy. According to MRI,investigators measure the optimal T2 signal intensity ratio (SIR) for the treatment of TAO, which may help to find a better treatment time for therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The diagnostic standard of TAO is according to Bartley's criteria.
  • Patients with active moderate-to-severe TAO based on 2016 EUGOGO guidelines.
  • None of the patients received any glucocorticoids therapy or orbital radiotherapy in the previous 3 months.

排除标准

  • NOSPECS is 0 or 1.Only signs,no symptoms.Signs include:reduced blink(Stellwag symptoms),two reduced cohesion(Mobius levy),moving slowly on the eyelids(Von Graefe sign),to the point of view,the forehead wrinkled skin should not(Joffroyv levy).
  • Suffering from other eye diseases or wearing contact lenses.
  • Suffering from other autoimmune diseases.
  • Acute and chronic infectious diseases.
  • Diabetic retinopathy or hypertensive fundus lesions.
  • Patients received orbital decompression or other orbital surgery.
  • Suffering from eye trauma or ocular surface disease.
  • Special occupants, and the working environment has obvious air pollution etc.

研究组 & 干预措施

Group Ia

Experimental

I:The increase of fat volume dominates .

a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks.

干预措施: Glucocorticoids (Drug)

Group Ib

Experimental

I:The increase of fat volume dominates. b:The "qod" protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months.

干预措施: Glucocorticoids (Drug)

Group IIa

Experimental

II:The increase of extraocular muscles volume dominates .

a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks.

干预措施: Glucocorticoids (Drug)

Group IIb

Experimental

II:The increase of extraocular muscles volume dominates . b:The "qod" protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months.

干预措施: Glucocorticoids (Drug)

结局指标

主要结局

Number of patients defined as Unchange for the Glucocorticoids Treatment based on the 7 parameters of eye assessment

时间窗: 2years

"Unchanged" was defined as no change or changes smaller than previously defined in any of the mentioned parameters.

Number of patients defined as Response for the Glucocorticoids Treatment based on the 7 parameters of eye assessment

时间窗: 2years

"Response" was defined as at least three of the following outcome measures: 1. reduction in lid width by at least 3 mm; 2. reduction in any of the class 2 NOSPECS signs by at least two grades; 3. reduction in proptosis by at least 2 mm; 4. reduction in intraocular pressure by at least 2 mm Hg; 5. improvement in CAS by at least two points; 6. improvement in diplopia (disappearance or degrade in degree); 7. improvement in visual acuity by 1 Snellen line.

Number of patients defined as Deterioration for the Glucocorticoids Treatment based on the 7 parameters of eye assessment

时间窗: 2years

"Deterioration" of each parameter was defined as follows: 1. increase in lid width by at least 3 mm; 2. increase in any of the class 2 NOSPECS signs by at least two grades; 3. increase in proptosis by at least 2 mm; 4. increase in intraocular pressure by at least 2 mm Hg; 5. increase in CAS by at least two points; 6. increase in diplopia (new onset or upgrade in degree); 7. decrease in visual acuity by 1 Snellen line.

次要结局

未报告次要终点

研究者

发起方
Jie Shen
申办方类型
Other Gov
责任方
Sponsor Investigator
主要研究者

Jie Shen

Vice President;Doctoral Supervisor

The Third Affiliated Hospital of Southern Medical University

研究点 (1)

Loading locations...

相似试验